{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect and review Subject Diary.', 'Assess treatment compliance.', 'Allocate study treatment through the IWRS.', '- In addition to study treatment for Visit 7 (Week 64) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 8 (Week 76).', 'Administer study treatment.', '5.4.1.8', 'Visit 8 (Week 76)', 'The following assessments will be conducted at Visit 8 (Week 76):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Amendment 2: 06 March 2019', '67', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Perform CV risk assessment.', 'Perform 12-lead ECG.', 'Collect samples for INR, aPTT, and fibrinogen.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for lipid panel and CV risk panel.', 'Collect samples for chemistry panel and hematology assessments.', 'Collect sample for HbA1c assessment (subjects with confirmed diabetes mellitus only).', 'Collect sample for analysis of ADAs.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect sample for urinalysis.', 'Collect and review Subject Diary.', 'Assess treatment compliance.', 'Allocate study treatment through the IWRS.', '- In addition to study treatment for Visit 8 (Week 76) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 9 (Week 88).', 'Amendment 2: 06 March 2019', '68', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Administer study treatment.', '5.4.1.9', 'Visit 9 (Week 88)', 'The following assessments will be conducted at Visit 9 (Week 88):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Assess Treatment Response', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only', 'Amendment 2: 06 March 2019', '69', 'Confidential']\n\n###\n\n", "completion": "END"}